De Giorgi Vincenzo, Trane Luciana, Pieretti Giulia, Santoro Nicola, Silvestri Flavia, Venturi Federico, Scarfì Federica, Maio Vincenza, Spinelli Giuseppe, Scoccianti Silvia, Guerrini Laura, Massi Daniela, Mazzini Cinzia, Doni Laura
Section of Dermatology, Department of Health Sciences, University of Florence.
Unit of Ocular Oncology - Eye Clinic, Neuromuscular and Sense Organs Department, Careggi University Hospital, Florence.
Dermatol Reports. 2021 Aug 5;13(3):9240. doi: 10.4081/dr.2021.9240. eCollection 2021 Nov 17.
The management of difficult-to-treat periocular basal cell carcinoma (BCC) becomes very challenging in cases of delayed diagnosis, leading to the development of locally advanced BCC. The aim of this study was to evaluate the outcomes of Hedgehog pathway inhibitors (vismodegib and sonidegib) treatment in patients affected by periocular locally advanced BCC. We focused on the common adverse events and their correlation with the administration schedule, to determine a management protocol specific for the periocular area. This observational prospective study included a single-center case series with patients who were histologically confirmed to have periocular or orbital locally advanced BCC, treated with Hedgehog pathway inhibitors. All patients benefitted in terms of regression or stabilization of the neoplasm. In the first months of treatment, the HPIs were well tolerated, and the first important side effects appeared after about 5 months of continuous use of the drug. These data could lead to a new type of therapeutic scheme where neoadjuvant therapy could be followed by pulse therapy as an adjuvant to surgery.
对于延迟诊断导致局部晚期基底细胞癌（BCC）发生的难治性眼周基底细胞癌患者，其治疗管理极具挑战性。本研究的目的是评估刺猬通路抑制剂（维莫德吉和索尼德吉）治疗眼周局部晚期基底细胞癌患者的疗效。我们关注常见不良事件及其与给药方案的相关性，以确定针对眼周区域的管理方案。这项观察性前瞻性研究纳入了一个单中心病例系列，患者经组织学确诊患有眼周或眼眶局部晚期基底细胞癌，并接受了刺猬通路抑制剂治疗。所有患者在肿瘤消退或稳定方面均有获益。在治疗的最初几个月，刺猬通路抑制剂耐受性良好，在持续使用该药物约5个月后出现了首批重要的副作用。这些数据可能会促成一种新型治疗方案，即新辅助治疗后采用脉冲治疗作为手术辅助治疗。
